Factors associated with Tdap vaccination receipt during pregnancy: a cross-sectional study.
Adult
Cross-Sectional Studies
Diphtheria-Tetanus-acellular Pertussis Vaccines
/ administration & dosage
Female
Gestational Age
Humans
Immunization
/ statistics & numerical data
Infant
Influenza Vaccines
Pregnancy
Pregnant Women
Retrospective Studies
Vaccination
/ statistics & numerical data
Whooping Cough
/ prevention & control
Young Adult
Immunization
Pertussis
Pregnancy
Tdap
Vaccination
Journal
Public health
ISSN: 1476-5616
Titre abrégé: Public Health
Pays: Netherlands
ID NLM: 0376507
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
17
03
2019
revised:
30
07
2019
accepted:
01
10
2019
pubmed:
15
11
2019
medline:
9
4
2020
entrez:
15
11
2019
Statut:
ppublish
Résumé
Pertussis morbidity and mortality disproportionately affect infants younger than 1 year, who constitute 70% of deaths from pertussis. In 2017, 43% of infants younger than 6 months diagnosed with pertussis were hospitalized. In 2012, the Advisory Committee on Immunization Practices recommended that all pregnant women should receive Tdap (tetanus-diphtheria-acellular pertussis) vaccine between 27- and 36-weeks gestation in an effort to reduce infant pertussis morbidity and mortality. However, Tdap vaccination rates among pregnant women remain far from robust. The aim of this study was to assess factors associated with maternal Tdap uptake to help providers identify best practices that can improve Tdap receipt and identify women at risk for not receiving this important vaccine. A retrospective cross-sectional study. A review of prenatal and delivery records was performed on all maternal-infant dyads with infants older than 36 weeks gestation admitted to the term nursery at Albany Medical Center from January 1, 2016 to April 16, 2016. A chi-squared analysis using STATA®, version 14.1, was performed to determine if any variables were associated with Tdap uptake, with statistical significance defined as P < 0.05. Multivariate analysis was performed to identify the variables which had the greatest effect on Tdap receipt. Tdap vaccine was received by 65.8% of pregnant women (n = 400) in the study; median gestational age of receipt was 30 weeks. Maternal influenza vaccine receipt, infant hepatitis B vaccine receipt, provider recommendation of Tdap vaccination, and on-site availability of Tdap vaccine were all positively associated with maternal Tdap receipt during pregnancy. Receipt of Tdap by pregnant women was highest in those who had received a provider recommendation about its benefits and who also received influenza vaccine during pregnancy. Because women who received the influenza vaccine themselves and also consented to have their infants receive the hepatitis B vaccine had significantly higher uptake rates, encouraging vaccines usage and combating vaccine hesitancy in general can improve Tdap uptake rates. A small, but statistically significant association with receipt of assisted reproductive technologies was also seen, meriting future research.
Identifiants
pubmed: 31726399
pii: S0033-3506(19)30318-X
doi: 10.1016/j.puhe.2019.10.001
pii:
doi:
Substances chimiques
Diphtheria-Tetanus-acellular Pertussis Vaccines
0
Influenza Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
38-44Informations de copyright
Copyright © 2019 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.